For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

Keyword

Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with r...

Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA

$Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL ( Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA )$

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC ( Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )

Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patient...

Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy

Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma ( Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy )

Treating patients with multiple myeloma in the real world

Dr Ajai Chari and Prof Roman Hájek

Treating patients with multiple myeloma in the real world ( Dr Ajai Chari and Prof Roman Hájek )

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine...

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )

KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma

Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain

KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma ( Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain )

Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients w...

Dr Naval Daver - MD Anderson Cancer Center, Houston, USA

Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML ( Dr Naval Daver - MD Anderson Cancer Center, Houston, USA )

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma

Prof Philippe Moreau - University of Nantes, Nantes, France

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )

ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexame...

Prof Efstathios Kastritis - University of Athens, Athens, Greece

ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly-diagnosed AL amyloidosis ( Prof Efstathios Kastritis - University of Athens, Athens, Greece )

The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blina...

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymp...

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

More from ecancer